Carol A. Ammon, AMP 149
Chairman and Founder
Endo Pharmaceuticals, Inc.
Carol A. Ammon is Chairman and Founder of Endo Pharmaceuticals Inc., a market
leader in pain management. Prior to forming Endo in a management buyout in 1997, Ms.
Ammon spent 23 years in the pharmaceutical division of E.I. du Pont de Nemours and
Company. She received the 2003
Greater Philadelphia Ernst & Young Entrepreneur Of The Year Award®, the 2005
Paradigm Award and was recently named one of Pennsylvania’s Best 50 Women in
Business.
She earned a BA from Central Connecticut State University, an MBA from
Adelphi University and completed the Advanced Management Program at Harvard
University. She serves on the boards of numerous civic, corporate and nonprofit
organizations.
John Carey
Senior Correspondent
Business Week
John Carey covers science, technology, medicine, and the environment for Business Week. He has written stories on everything from sequencing the human genome and global warming to tobacco regulation and election technology. He previously worked at The Scientist, National & International Wildlife, and Newsweek. His stories have won awards from the Deadline Club, the American Institute of Biological Sciences, and others. He has degrees in biochemistry (BA, Yale University), marine biology (MSc, University College of North Wales), and forest ecology (MFS, Yale School of Forestry & Environmental Studies). »back to top
Prithviraj Chavan
Minister of State, Prime Minister's Office, India
Prithviraj Chavan, Minister of State in the Prime Minister’s Office, is a senior politician of the Indian National Congress Party from Maharashtra. A member of the Upper House of Parliament, he has served on many important Parliamentary Committees in fields including public finance, international trade and technology. He graduated with honors in Mechanical Engineering from the Birla Institute of Technology and Science, Pilani, and holds a MS in Engineering from the University of California, Berkeley. He has developed defense electronic systems for air defense, missile control and aircraft test equipment. »back to top
Deirdre
Connelly, AMP 158
President, Lilly USA
Eli Lilly and Company
Deirdre Connelly is president of Lilly USA, the company’s largest and most influential affiliate. She is the first woman to lead Lilly’s U.S. operations—a job she assumed in 2005. Born in Puerto Rico, she received a bachelor's degree in economics and marketing from Lycoming College. She graduated from the Harvard University's Advanced Management Program in 2000. She joined Lilly in 1983 as a sales representative. Since then, she has served in a number of leadership roles, including general manager of Eli Lilly Puerto Rico, head of Lilly’s U.S. women’s health business unit and senior vice president of human resources. »back to top
Robert A. DeNoble, MBA '72
President and CEO
The Marino Foundation for Integrative Medicine, Inc.
President, Harvard Business School Health Industry Alumni Association
Robert DeNoble has over 25 years of experience as a senior executive of healthcare organizations and as a consultant to health care providers and early stage biotech companies. In addition to his role as CEO of the Marino Foundation, he serves as a principal with RDA Healthcare Consulting, Inc., a company he co-founded to provide strategic, operational and financial management services to healthcare organizations. Prior to his current positions, he held senior positions with KPMG, LLP, Rhode Island Hospital, and McLean Hospital. He serves on the Board of the Austen Riggs Center, a national renowned psychiatric hospital located in western Massachusetts. »back to top
David A. Dodd, AMP 156
Former President, CEO & Director
Serologicals Corporation
During David A. Dodd's six-year leadership, Serologicals Corporation went from an $85 million to a $1.4 billion company, with its acquisition by Millipore Corporation. He was previously President and CEO of Solvay Pharmaceuticals, Inc., and a member of the Management Board for the Pharmaceutical Sector for Solvay S.A. He also was Chairman of the Board of Unimed Pharmaceuticals, Inc., a Solvay subsidiary. He was awarded the 2005 GBP Biomedical Industry Growth Award, and the 2005 Oglethorpe Award from the Atlanta Chapter of the British American Business Group. He holds a Bachelor of Science and Master of Science from Georgia State University and completed the Harvard Business School Advanced Management Program. »back to top
Beatrice Ellerin, MBA '95
Managing Director, Interbrand Wood
Founder, Past President, and Chairman, HBS Health Industry Alumni Association
Beatrice Ellerin, known as Bunny, heads up the rxmark division at Interbrand Wood, a leading healthcare branding agency. She focuses on brand research and works closely with senior management to drive business growth. Previously, she was Executive Director of PPD Online Marketing & Education, Inc., where she directed corporate strategy, business development and global marketing. She has been a Vice President at Vivra Specialty Partners, where she managed risk contracts and clinical data reporting for 14 single specialty networks. She received a BA in Political Science from Columbia University. As Chairman, Founder and past President of HBS Health, she led the group's growth into a major HBS alumni association. »back to top
Jean-Pierre Garnier, PhD
Chief Executive Officer
GlaxoSmithKline
JP Garnier is CEO of GlaxoSmithKline, the world's second-largest pharmaceutical company. Prior to leading GSK, he was Chief Operating Officer of SmithKline Beecham, where he had served as President of its North American pharmaceutical business. He began his career at Schering-Plough in a variety of management positions. He was appointed to Chancellor Gordon Brown’s UK Advisory Council and named one of 50 “Stars of Europe” by Business Week magazine. He earned a PhD in pharmacology and an MS in pharmaceuticals science from the University of Louis Pasteur in France, and an MBA from Stanford University as a Fulbright Scholar. He serves on the Boards of the United Technologies Corporation, Committee to Encourage Corporate Philanthropy and Eisenhower Exchange Fellowships. »back to top
Ginger L. Graham, MBA '86
Chief Executive Officer
Amylin Pharmaceuticals, Inc.
Ginger L. Graham is CEO of Amylin Pharmaceuticals, Inc., a company developing innovative medicines for people with metabolic diseases. She was formerly Group Chairman, Office of the President for Guidant Corporation, and was also with Eli Lilly and Company. She serves on the Board of Directors for Amylin Pharmaceuticals, PhRMA (Pharmaceutical Research and Manufacturers of America), the California Healthcare Institute and the California Council on Science and Technology. She also serves on several advisory boards, including the Harvard Business School Board of Dean's Advisors and the Harvard Business School Health Industry Alumni Advisory Board. She received a BS in agricultural economics from the University of Arkansas, and holds a Harvard MBA. »back to top
Scott Hensley
Staff Journalist
The Wall Street Journal
Scott Hensley, a reporter in The Wall Street Journal's New York bureau, covers health care and the pharmaceutical industry. He writes "Follow the Money," a column giving a behind-the-scenes look at what drives decisions in the health-care industry, which appears on The Wall Street Journal Online at wsj.com. He also appears on CNBC, a cable news channel. Born in Texas, he earned a bachelor's degree in natural sciences from Johns Hopkins University and a master's degree from Columbia University's Graduate School of Journalism. Before becoming a journalist, he worked for Siemens Medical Systems, a medical equipment maker, for 10 years. »back to top
Anula Jayasuriya, MD, PhD, MBA '93
Managing Director, Evolvence India Life-Science Fund
Co-Chair, HBS Health 7th Annual Healthcare Conference
Anula Jayasuriya is a founding partner the Evolvence India Life-Science Fund. She was previously a partner with Skyline Ventures, and prior to that with the German–US venture capital firm TVM. She has been VP-Corporate development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche. She received a BA from Harvard summa cum laude, and an MD and PhD (in Microbiology and Molecular Genetics) from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital. Besides her MBA with distinction from HBS, she also holds a MPhil in pharmacology from the University of Cambridge, England. She serves on the Board of HBS Health.
»back to top
Habil Khorakiwala, AMP 90
Chairman
Wockhardt Group
Habil Khorakiwala is chairman of Wockhardt Group, a leading Indian pharmaceutical and healthcare enterprise. Khorakiwala has a Masters degree in pharmaceutical science from Purdue University and is an alumni of Harvard Business School. He is Senior Vice President of the Federation of Indian Chambers of Commerce and Industry, and member of the National Manufacturing Competitiveness Council set up by the Indian government. Europe and the US contribute half of Wockhardt Limited’s sales of $325 million. Wockhardt Hospitals, the group’s healthcare delivery arm, an associate of Harvard Medical International, operates super-specialty hospitals in six cities in India. Khorakiwala lives in Mumbai with wife Nafisa, two sons, a daughter and two grandchildren.
»back to top
Wolfgang Klietmann, MD, OPM 12
President and Medical Director, Mediconsulting, Inc.
Co-Chair, HBS Health 7th Annual Healthcare Conference
Wolfgang Klietmann heads an international healthcare consulting company and is an appointed Lecturer in Pathology at Harvard Medical School. Previously on staff of the Department of Pathology at Massachusetts General Hospital, he also performed research as an Associate Scientist at the Wistar Institute of the University of Pennsylvania, headed a research group at the Max-Planck-Institute for Virus Research, and served on the medical faculty of the University of Tuebingen. He was Founder and Physician-in-Chief of a leading Institute of Laboratory Medicine in Germany. He received his medical education at the University of Freiburg (Germany), and at the Sorbonne and the University of Paris Medical School (France). He is a Fellow of the College of American Pathologists. He was recently elected Co-Chair of the Community Relations Committee and ex officio member of the Executive Committee for the 2007 BIO International Convention. »back to top
Jay O. Light
Dean, Harvard Business School
George F. Baker Professor of Administration
Jay Light, a distinguished member of the HBS faculty for 35 years, has held a number of senior leadership roles, including most recently Senior Associate Dean, Director of Planning and Development. Previously, he served as Chairman of the Finance Area, and Senior Associate Dean, Director of Faculty Planning at HBS, and he has taught extensively in the MBA and Executive Education programs. He is a Director of the Harvard Management Company, a Director of Partners HealthCare (the Mass General and Brigham & Women's Hospitals) and the Chairman of the Investment Committee of Partners HealthCare. He is a graduate of Cornell University and Harvard University. »back to top
Klaus Lindpaintner, MD, MPH
Head, Roche Genetics and Director, Roche Center for Medical Genomics
F. Hoffman–La-Roche AG
Klaus Lindpaintner received an MD from the University of Innsbruck Medical School and a degree in Public Health from Harvard University. He is board certified in internal medicine, cardiology, and genetics in the United States and Germany. He practiced cardiology and pursued research in cardiovascular disease and molecular genetics and genetic epidemiology, most recently as an Associate Professor of Medicine at Harvard Medical School. He joined Hoffman-La Roche Pharmaceuticals in Basel as Head of Preclinical Research in Cardiovascular Diseases. Since 1998, he has served as Head of Roche Genetics, and since 2001, also as Director of the Roche Center for Medical Genomics, coordinating the company’s efforts and activities in genetics, genomics, proteomics, and associated disciplines. »back to top
Martin Mackay, PhD
Senior Vice President, WW Research and Technology
Pfizer
Martin Mackay earned a Microbiology First Class Honors Degree at Heriot-Watt University and a PhD in molecular genetics at the University of Edinburgh. Between degrees he worked in Antibacterial Discovery at Beecham Pharmaceuticals in Surrey, UK. He conducted his postdoctoral research fellowship working on malarial vaccines at the University of Edinburgh He joined the Advanced Drug Delivery Research Unit at Ciba-Geigy in Sussex, UK, became Head of Drug Preformulation and Delivery, then moved to Ciba headquarters as Head of Molecular and Cell Biology, CNS Research. He joined Pfizer as Director of Discovery Biology, and has served as Senior Director, Head of Biology; Vice President, UK Discovery; and Senior Vice President, WW Discovery. »back to top
Martin McGlynn
President and Chief Executive Officer
StemCells, Inc.
Since January 2001, Mr. Mc Glynn has been President, CEO and a Director of StemCells, Inc. Previously, he served as Chief Executive Officer of Pharmadigm, a privately held, biopharmaceutical company. His earlier positions include President of Anaquest, a BOC Healthcare company, VP of Abbott International and President and General Manager of Abbott, Canada, Ltd., and General Manager, Abbott Ireland Ltd. Prior to that he was General Manager, The International Meat Company in Dublin and also held various senior management position with Becton, Dickinson and Company in Ireland. A native of Dublin, Ireland, he is a graduate of University College, Dublin. He is a former member of the Board of Directors of the Confederation of Irish Industries and the Pharmaceutical Manufacturers Association of Canada. »back to top
Douglas Melton, PhD
Thomas Dudley Cabot Professor in the Natural Sciences, Harvard University
Co-director, Harvard Stem Cell Institute
Embryologist Douglas Melton studies genes and cells that make pancreatic tissue in relation to diabetes. He is the Chair of the Harvard Life Science Departments in the Faculty of Arts and Sciences, an Investigator of the Howard Hughes Medical Institute, and Co-director of the Harvard Stem Cell Institute. He holds a bachelor's degree in biology from the University of Illinois, a BA in history and philosophy of science from Cambridge University, and a PhD in molecular biology from Trinity College and the MRC Laboratory of Molecular Biology. His awards include the Lounsberry Medal from the National Academy of Sciences and the Joslin Medal.
»back to top
James C. Mullen
President and Chief Executive Officer
Biogen Idec, Inc.
James Mullen joined Biogen, Inc., in 1989, and was named CEO in 2000 and Chairman in 2002. He has held the positions of President and COO; VP, International; VP, Operations; and Director, Facilities and Engineering. In 2003, he helped spearhead the merger of Biogen with IDEC Pharmaceuticals Corp. Today, Biogen Idec is a global biotechnology leader creating new standards of care in oncology, neurology and immunology. He is Chairman of the Board of the Biotechnology Industry Organization, and a member of the Board of Directors of PerkinElmer, Inc., and the Biomedical Sciences Careers Program. He holds a BS in Chemical Engineering from Rensselaer Polytechnic Institute and an MBA from Villanova University. »back to top
Satish Reddy
Managing Director and Chief Operating Officer
Dr. Reddy's Laboratories
Satish Reddy joined the company as Executive Director in 1993, responsible for manufacturing operations of active pharmaceutical ingredients (API) and formulations, research and development activities, and new product development. He presided over the company's successful transition from a predominantly API manufacturer to a more value-added, finished dosages producer. Today, Dr. Reddy’s continues its journey by leveraging on its ‘Low Cost, High Intellect’ advantage by foraying into new markets and new businesses, spearheaded by Satish as the Managing Director & Chief Operating Officer. He has a MS degree in Medicinal Chemistry from Purdue University and a B Tech degree in Chemical Engineering from Osmania University, Hyderabad.
»back to top
John A. Quelch, PhD
Lincoln Filene Professor of Business Administration
and Senior Associate Dean
Harvard Business School
An expert on international marketing and branding, Professor Quelch is examining the genesis and management of blockbuster brands across a wide range of industries, as well as marketing practices and success factors of global nongovernmental organizations. He authored or coauthored more than 20 books, including The New Global Brands: Managing Non-Governmental Organizations in the 21st Century (with N. Laidler) and The Global Market: Developing a Strategy to Manage Across Borders (with R. Deshpandé). He is chairman of the Massachusetts Port Authority and a non-executive director of The Pepsi Bottling Group, WPP Group, Gentiva Health Services and Inverness Medical Innovations. »back to top
Christopher Thomas Scott
Executive Director
Stanford Program on Stem Cells and Society
Also a Stanford University lecturer, Christopher Scott wrote the acclaimed Stem Cell Now: From the experiment that shook the world to the new politics of life (Penguin). He was the scientific founder of Acumen Sciences, and executive editor of the award-winning Acumen Journal of Sciences. He was Assistant Vice Chancellor at the University of California, San Francisco, and was a senior administrator at Stanford, where he held numerous positions. He holds BS and BA degrees in biological sciences from Colorado University, an MA from Stanford in biomedical policy, and he completed Stanford’s Executive Management Program. Scott has been featured in the national media, including Time, U.S. News and World Report, National Public Radio, UPI and Fox News.
»back to top
Shivinder Mohan Singh
Managing Director
Fortis Healthcare Ltd and Escorts Heart Institute & Research Center (EHIRC)
Shivinder Singh is Managing Director of Fortis Healthcare Ltd and Escorts Heart Institute & Research Center (EHIRC). He is spearheading the Healthcare Group of Fortis Healthcare & SRL Ranbaxy with very aggressive growth plans. He recently led the acquisition of Escorts Heart Institute & Research Center (EHIRC), to make Fortis the second largest healthcare network in India and the biggest cardiac program in the world. An Honours Graduate in Mathematics from St. Stephens College, Delhi, he received an MBA with specialization in health sector management from the Fuqua School of Business, Duke University. »back to top
Josef H. von Rickenbach, MBA '81
Founder, Chairman, and CEO, PAREXEL International Corporation
Josef von Rickenbach heads PAREXEL, one of the world's largest bio/pharmaceutical outsourcing companies providing expertise-based product development and marketing outsourcing services to the international pharmaceutical, biotechnology, and medical device industries. His management of the company's expansion was recognized when he was named the Ernst & Young New England Region Entrepreneur of the Year in 1997. He began his career with Schering-Plough, then held positions with ENSECO (formerly ERCO). He currently serves as Chairman of the Association of Clinical Research Organizations (ACRO). He holds a Bachelor of Business Administration from the Lucerne College of Industry Economics and Administration in Switzerland and an MBA from Harvard University.
»back to top
Steven Wardell, MBA '00
Principal
Apeiron Partners, LLC
Roundtable Chair, HBS Health 7th Annual Healthcare Conference
Steven Wardell is a health-industry investment banker with successful industry operating experience. He is a Principal at Apeiron Partners, a Boston-based life-science investment bank and venture capital fund. He works with health-industry leaders on business development and value-creating corporate-finance transactions and fills operating roles at newcos. Previously, he worked on Wall Street where he participated in over $20 billion worth of international M&A and financing transactions at Citigroup in healthcare, technology, and other sectors. He holds an MBA from Harvard Business School, an MPhil from Cambridge University, and a BA from Harvard College. He is a graduate of MIT’s Entrepreneurship Lab. »back to top
Leslie E. Wolf, JD, MPH
Assistant Adjunct Professor
University of California, San Francisco
Leslie Wolf is Assistant Adjunct Professor in the Program in Medical Ethics at the University of California, San Francisco. Before joining the UCSF faculty, she clerked for the Massachusetts Appeals Court, was a litigator with a San Francisco law firm, and was a Greenwall Fellow in Bioethics and Health Policy. At UCSF, she serves on the Chancellor’s Advisory Committee on Ethical Issues in Gamete, Stem Cell, and Embryo Research and the Committee on Human Research. She has published several articles on ethics and oversight of stem cell research. She also conducts research on various research ethics topics. »back to top
Entertainment
Ute Gfrerer is an acclaimed singer of opera, operetta, musicals and cabaret. She was born in Austria and studied music in Southern California. An ensemble member of the Viennese Volksopera, she has performed in major opera houses and concert halls worldwide, including Zurich, the Barbican Hall in London, and the Alte Oper Frankfurt. She has worked under the direction of Oscar winner Klaus Maria Brandauer as well as leading conductors. Her repertory includes the role of Susanna in "The Marriage of Figaro" and Eliza Doolittle in "My Fair Lady." She also specializes in the music of Kurt Weill. www.ute-gfrerer.com
©2006 Harvard Business School Health Industry Alumni Association
